Halozyme Therapeutics (HALO) traded up 1.89 % during a 24 hours period ending at 09:15 PM Central Europe on Tuesday 27th. One Halozyme Therapeutics stock can currently be bought for about USD 128.46 on popular exchanges. Current supply of Halozyme Therapeutics stocks is 113.5 mn. Halozyme Therapeutics has a current market capitalization of USD 14.4 bn and approximately USD 158.4 mn worth of Halozyme Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Halozyme Therapeutics has traded 13.39 % up. Simple moving average of last 200 days is at USD 82.22. The highest price of past 52 weeks was recorded at USD 128.11 on 10/26/2026. 52 weeks low was at USD 61.23 on 12/11/2025.
Here is how related stocks have performed in the past 24 hours:
Jacobs (J) traded up 1.43 % and now trades at USD 147.57. Jacobs has a market capitalisation of USD 17.1 bn. Current price/earnings ratio for Jacobs is 48.39.
Rivian Automotive (RIVN) traded down -3.38 % and now trades at USD 11.82. Rivian Automotive has a market capitalisation of USD 17.1 bn. Volkswagen is reportedly evaluating the use of a software architecture developed with its Chinese partner Xpeng for a large portion of its upcoming electric vehicles in Europe. The proposal, which could affect three‑quarters of models from its core brands, raises questions about the current collaboration with Rivian that underpins the group’s Western‑market software strategy. Rivian’s joint venture with Volkswagen has focused on developing a separate technology platform for the U.S. and European markets, a partnership backed by a substantial investment. Volkswagen’s consideration of the Chinese‑derived system may influence the scope of the Rivian collaboration, though no formal change has been announced. The potential shift reflects the growing importance of software platforms in the competitive electric‑vehicle landscape.
Itt (ITT) traded up 0.36 % and now trades at USD 194.01. Current market capitalisation for Itt is USD 17.1 bn. Current price/earnings ratio for Itt is 37.87.
Clean Harbors (CLH) traded down -0.52 % and now trades at USD 311.8. Clean Harbors has a market capitalisation of USD 16.8 bn. Clean Harbors has a current price to earnings ratio of 38.59. CLEAN HARBORS INC reported a change in executive leadership, with the previous chief executive stepping down at the end of the year. The board appointed a new CEO, who brings extensive experience in finance and corporate strategy, previously serving as a chief financial officer at a major Swiss bank. The transition follows a period of significant growth for the company, during which its assets and market presence expanded markedly under the former CEO’s tenure. The outgoing executive will continue to support the firm as an adviser, focusing on stakeholder relations and governmental affairs. The company’s management emphasized a commitment to sustaining its momentum, enhancing profitability, and maintaining disciplined financial governance while pursuing further development of its core business portfolio.
Genuine Parts (GPC) traded up 0.16 % and now trades at USD 121.74. Genuine Parts has a market capitalisation of USD 17 bn. Current price/earnings ratio for Genuine Parts is 553.99.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company engaged in developing products for the diabetes, cancer, dermatology, and drug delivery markets. Its platform technology revolves around recombinant human hyaluronidase along with additional enzymes, which the company applies to its proprietary programs and partnerships with pharmaceutical companies. You can find more information about this company and its offerings on its website, located at www.halozyme.com . Halozyme Therapeutics Inc. is Nasdaq-traded.